There are currently 2877 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
NCT06321601
Recruiting
The main objective of this study is to explore the efficacy of avacopan in participants affected by AAV.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/06/2025
Locations: Texas Childrens Hospital, Houston, Texas
Conditions: Vasculitis
Register for Updates
Patient Priorities for Survivorship Care in Older Breast Cancer Survivors
NCT06478589
Recruiting
The objective of this study is to adapt the Patient Priorities Care (PPC) framework to breast cancer survivorship via a user-centered approach, through an iterative process in which patients and their physicians help to refine and modify the intervention. A second objective is to evaluate the feasibility and effectiveness of the adapted PPC framework in breast cancer survivorship for older adults.
Gender:
FEMALE
Ages:
Between 65 years and 100 years
Trial Updated:
08/06/2025
Locations: UT Physicians Family Medicine Bayshore, Houston, Texas +1 locations
Conditions: Breast Cancer Survivorship
Register for Updates
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
NCT06236724
Recruiting
To learn if asciminib can help to control CML. The safety and effects of this drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Myeloid Leukemia
Register for Updates
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025
Recruiting
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Houston Methodist Hospital, Houston, Texas +3 locations
Conditions: Solid Cancer
Register for Updates
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210
Recruiting
This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Houston Methodist Cancer Center, Houston, Texas +1 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491
Recruiting
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Gender:
MALE
Ages:
Between 18 years and 130 years
Trial Updated:
08/06/2025
Locations: Research Site, Houston, Texas +2 locations
Conditions: Metastatic Castration-Sensitive Prostate Cancer
Register for Updates
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916
Recruiting
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the bra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma
Register for Updates
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247
Recruiting
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/06/2025
Locations: Houston Methodist Hospital, Houston, Texas +1 locations
Conditions: Leukemia
Register for Updates
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
NCT06641089
Recruiting
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: Clinical Site, Houston, Texas
Conditions: Arthritis, Psoriatic
Register for Updates
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
NCT06836232
Recruiting
This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Approximately 30 patients will take VTX2735. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 6-week Open Label Treatment period (a participant receives active Dose A), a 7-week Extension Treatment period (a participant meets criteria for continuing and receives active Dose A) and a 14-day Follow-Up Period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/06/2025
Locations: Local Site #840001, Houston, Texas
Conditions: Recurrent Pericarditis
Register for Updates
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06638307
Recruiting
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2025
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Breast Cancer
Register for Updates
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
NCT06668584
Recruiting
The goal of this clinical research study is to learn about the safety and tolerability of giving olutasidenib to patients with IDH1-mutated myeloid malignancies as maintenance therapy after they receive a stem cell transplant.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/06/2025
Locations: The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Myeloid Malignancies
Register for Updates